Perspective Therapeutics updates ASCO 2026 data; VMT-α-NET shows deepening responses in NETs

Perspective Therapeutics, Inc.

VMT-α-NET (212Pb for SSTR2+ NETs) shows best response deepens over time; durable disease control across doses; stable renal function in 68 patients.
VMT01 (212Pb for MC1R+ melanoma) shows preliminary anti-tumor activity at 3.0 mCi dose; well-tolerated with TEAEs in ≥10% of patients.
PSV359 (212Pb targeting FAP-ɑ) enters Phase 1/2a for advanced solid tumors with improved tumor retention.
Pipeline also includes CCK2R81 for medullary thyroid cancer and combination with immune checkpoint inhibitors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.